Access to POEMs and Essential Evidence Plus will no longer be included in CMA membership as of Dec. 1, 2023.
Clinical Question
Does simply giving a polypill containing aspirin, an angiotensin-converting enzyme inhibitor, and a statin improve outcomes more than physician-directed care as secondary prevention in patients who have had a recent acute myocardial infarction?
Bottom line
A polypill containing aspirin, a high-intensity statin, and an angiotensin-converting enzyme inhibitor resulted in fewer cardiovascular events in patients who had an acute myocardial infarction within the previous 6 months. The simplicity of this approach is appealing. 1b
Reference
Study design: Randomized controlled trial (single-blinded)
Funding: Government
Setting: Outpatient (any)
Synopsis
This multicountry European study identified 2499 participants with a history of myocardial infarction in the past 6 months, older than 75 years, or older than 65 years with at least one risk factor (diabetes, mild to moderate kidney failure, previous myocardial infarction, previous stroke, or previous revascularization). They were randomized into 1 of 2 groups. The first group received a polypill containing aspirin (100 mg), ramipril (2.5 mg, 5 mg, or 10 mg), and atorvastatin (40 mg). The atorvastatin dose could be reduced to 20 mg at the discretion of the investigators, and the target dose for ramipril was 10 mg. The second group received usual care based on European guidelines. The average age of participants was 75 years, 69% were men, and more than 98% were white. Groups were balanced at baseline, outcomes were assessed by a committee masked to treatment group, and the analysis was by intention to treat. Participants were followed up for a median of 3 years. In the polypill group, 92% of patients received the 40-mg dose of atorvastatin; in the usual care group, 83% of patients received what was defined as a high-intensity statin. The use of aspirin was similar between groups. Most patients in the polypill group received ramipril at a 2.5-mg or 5-mg dose. The primary outcome of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or urgent revascularization occurred less often in the polypill group (9.5% vs 12.7%; P < .001; number needed to treat [NNT] = 31). All the components of the composite decreased similarly, including cardiovascular death (3.9% vs 5.8%; HR 0.67; 0.47 - 0.97; NNT = 53). However, you have to die of something: There was a trend toward more noncardiovascular deaths (5.4% vs 3.7%; HR = 1.42; 0.97 - 2.07) and no difference in all-cause mortality.
Reviewer
Mark H. Ebell, MD, MS
Professor
University of Georgia
Athens, GA
Comments
Appealing to whom?
Another Big Pharma classic move.
Polypill
This study is misleading as it compares a drug to visits with a physician.
Polypill
What about side effects of treatment
Polypharmacie en une pilule unique
Rendre les traitements plus simples en offrant qu’une pilule rend l’observance des patients bien plus simple et cet article va dans ce sens! Maintenant il faudra qu’une compagnie générique soit capable de le faire à pris intéressant pour rendre le traitement possible
Considérant les problèmes de…
Considérant les problèmes de compliance, ça peut être une avenue à exploiter
polypill and cvs outcomes post mi
lower events than physician directed care